JPRN-UMIN000033288招募中未知
Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibody - JRC-IO-A
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient whose administration of immune checkpoint inhibitor is contraindicated. 2. Patient with a history of cardiac function abnormality (acknowledging abnormality requiring treatment by electrocardiogram) or a history of myocardial infarction within 6 months before registration Patient with uncontrolled angina pectoris or heart failure. Patients with active duplicated cancers (excluding carcinoma within the carcinoma and duplicate carcinoma with no recurrence for more than 5 years). 3. Cases with complications of infection or patients suspected of having infection with fever 38 degrees Celsius or higher. 4. Pregnant women, patients who may be pregnant, breastfeeding patients. 5. Other patients judged inappropriate by the attending physician due to serious complications.
研究者
相似试验
招募中
不适用
Prospective study of anti-PD-1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-L1 antibodylung cancerJPRN-UMIN000033657Japanese Red Cross Medical Center30
已完成
不适用
Prospective pilot study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously responded to anti-PD-1 antibodyadvanced non-small cell lung cancerJPRN-UMIN000031888Saitama medical university International medical Center20
招募中
不适用
Prospective observational study of anti-PD-L1 antibody drug atezolizumab for non small cell lung cancerJPRN-UMIN000035616Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine100
暂停
2 期
Efficacy of anti-PD-L1 antibody in anti PD-1 antibody resistant non-small cell lung canceron-small cell lung cancerJPRN-jRCTs031180055Horiike Atsushi30
进行中（未招募）
1 期
eo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin - NeoTRIPaPDL1 (Neoadjuvant therapy in TRIPle negative breast cancer with antiPDL1)EUCTR2014-005017-23-ITFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI272